Aprocitentan
A dual endothelin receptor antagonist that blocks both ETA and ETB receptors to relax blood vessels and lower blood pressure in patients with resistant hypertension. It represents a new mechanism for treating hard-to-control high blood pressure.
Peso molecular
546,2000 g/mol
LogP
2,40
TPSA
151,00 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estructura 2D
Cite this structure
Embed this structure
SMILES
NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1
InChI
InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24)
Molecular Formula
C16H14Br2N6O4S
HBD / HBA
2 / 10
Enlaces Rotables
8
Átomos Pesados
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A dual endothelin receptor antagonist that blocks both ETA and ETB receptors to relax blood vessels and lower blood pressure in patients with resistant hypertension. It represents a new mechanism for treating hard-to-control high blood pressure.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Aprocitentan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2165326. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25099191. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="aprocitentan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/aprocitentan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/aprocitentan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/aprocitentan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="aprocitentan"></drugfyi-drug>